Impax Laboratories, Inc. is an integrated specialty pharmaceutical company focused on developing, manufacturing and marketing generic and brand pharmaceutical products. We operate two divisions: Impax Generics and Impax Specialty Pharma. The Impax Generics division concentrates on developing, manufacturing, selling and distributing complex solid dose and alternative dosage form products. The Generics portfolio covers a broad range of therapeutic areas with products that have technically challenging drug-delivery mechanisms or unique development formulations. We plan to continue to expand our portfolio by primarily targeting high revenue potential products, including products with the potential to be first-to-file or first-to-market, providing certain competitive advantages. The Impax Specialty Pharma division is primarily focused on the development and promotion through our specialty sales force of proprietary branded pharmaceutical products for the treatment of central nervous system (CNS) disorders and other specialty segments. We believe that we have the research, development and formulation expertise to develop branded products that will deliver significant improvements over existing therapies. We plan to continue investing in our development pipeline, both internally and through acquisitions and partnerships primarily focused on late-stage and next generation product opportunities. Impax is always striving to fine-tune all aspects of our business in order to remain a vital contributor in our industry. We are transforming our culture to continually focus on quality and drive ongoing improvement to deliver sustainable results for our patients, customers, healthcare providers, regulators and stockholders, without compromise or exceptions. We are committed to making a difference by developing and investing in our employees in order to retain and attract top talent and nurture employee growth that will support the long-term success of the company.